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ABSTRACT 
 BACKGROUND 
Nature cure is a constructive method of treatment which aims at removing the 
basic cause of disease through the rational use of the elements freely available in nature. 
In hydrotherapy, water applications are made in cold, neutral and hot temperatures to 
produce thermic and circulatory reactions in the body. Cold hydriatic applications are 
tonic by reaction and used in eliminative and constructive phases. Hot applications, 
though atonic by reaction, are helpful in mitigating aches, pains and relieve internal 
congestions. Hydrotherapy is applied in the form of packs, steam baths, sitz bath, head 
or foot baths, bandages (wet or dry), fomentations and poultices and rubbings and water 
potations. GH pack seems to be effective, which is evident in one study which focused 
on GH pack as an additional treatment in patients with diabetes mellitus.  
OBJECTIVES 
The aim of the study is to evaluate the Fasting blood sugar level and Post Prandial 
blood sugar level in type II diabetes mellitus patient before and after the treatment.  
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MATERIALS AND METHODOOGY 
The hot water bag (98 to 104 degree F) is kept on the abdominal region, covering 
the epigastric region, left and right hypogastric region, left and right lumbar region 
and umbilical region. The ice bag (55 to 65 degree F) covers the region of lumbar 
vertebrae L2, L3, L4 and L5. The treatment is administered in supine lying position, 
where the hot fomentation bag is kept over the abdominal region and then the ice 
bag on lower back region. The patients are then covered with cotton cloth and 
wrapped with woollen blanket. 
RESULT 
The study showed the presence of significant reduction in blood glucose level in  
patients who had taken GHPK than the blood sugar level of patients who underwent 
other complementary therapy. 
CONCLUSION 
The study concludes that GHPK is more effective than other treatment in 
reducing the treatment of T2 diabetes mellitus by giving a significance reduction in 
the FBS and PPBS. 
KEY WORDS: 
GHPK, FBS, PPBS 
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1. INTRODUCTION 
Diabetes mellitus is a metabolic syndrome which is due to the deficiency of 
insulin. Diabetes mellitus is characterized by hyperglycaemia. Long standing 
complications of diabetes can result in the dysfunction and/or damage of eyes, 
kidneys, heart, blood vessels and the nervous system(Canivell & Gomis, 2014; 
Davidson, 2010). The prevalence of diabetes is increasing throughout the world. In 
2011, 366 million people had diabetes. By 2030 the prevalence of diabetes is 
expected to reach 552 million. 
Diabetes is a major cause of morbidity and mortality; these outcomes are not due 
to the immediate effects of the disorder. They are instead related to the diseases that 
develop as a result of chronic diabetes mellitus. These include diseases of 
large blood vessels (macrovascular disease, including coronary heart 
disease and peripheral arterial disease) and small blood vessels (microvascular 
disease, including retinal and renal vascular disease), as well as diseases of the 
nerves. 
Diabetes mellitus comprises a group of metabolic disorders. Diabetes leads to 
many complications if untreated. Acute complications of diabetes are diabetic 
ketoacidosis, hyperosmolar, hyperglycaemic state or death(Harrison, n.d.). Long 
term complications of diabetes are stroke, cardiovascular disease, foot ulcers, 
chronic kidney diseases and damage to the eyes. 
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The people affected by diabetes worldwide was estimated to be for 25 million 
people by 2017. This is about 8.8 % of the adult population. The prevalence of 
diabetes is equal in both males and females. This rate will still rise in the future. 
Person with diabetes have the risk of early death. The death  rate due to diabetes 
was approximately 3.2 to 5.0 million deaths in 2017. It is expected that the 
prevalence of diabetes is increasing fast in Asia and Africa. The diabetes cases may 
increase globally by 48 percentage from 2017 to 2045. Urbanisation and lifestyle 
changes like less physical activity, increased sedentary lifestyle, global nutrition 
transition, intake of “Western style” diet like food which are rich in energy-dense 
and food that lacks or poor in nutrients are some of the reasons for the increase in 
weight among people with diabetes. 
Lifestyle management of type II diabetes mellitus 
Lifestyle management is the corner-stone of clinical care in the management of 
diabetes mellitus. Evidences from large clinical trials emphasis on lifestyle 
management in type 2 diabetes mellitus. The primary lifestyle managements in the 
management of diabetes and prevention of cardiovascular risk focuses on 
components like calorie restriction, increased energy expenditure through increased 
physical activity and behaviour changes. 
Nature cure is a constructive method of treatment which aims at removing the 
basic cause of disease through the rational use of the elements freely available in 
nature. It is not only a system of healing, but also a way of life, in tune with the 
internal vital forces or natural elements comprising the human body. 
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Figure 1: Protocol of anti-hyperglycaemic therapy in adults with type 2 diabetes 
mellitus. Lifestyle management forms an important part from the start of the 
protocol 
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There are various modes of treatment of diabetes mellitus in naturopathy. 
Naturopathic treatment modalities focus on lifestyle modification aimed at treating 
diseases, promotion of positive health and prevention of diseases and disease 
complications.  Hydrotherapy is also a treatment which is used in the treatment of 
diabetes mellitus. It consists of a combination of hot and cold treatment. It uses its 
temperature effects in treating the condition. These form of water applications are 
in practise since old age days. It uses its temperature effects in all its form like solid, 
liquid, ice, vapour, and steam internally and externally. Hydrotherapy is given in 
different temperatures. The temperature at which the treatments are given are given 
in the table below. Gastrohepatic pack is one of the hydrotherapy treatments which 
is used in the treatment of diabetes mellitus. 
Naturopathic treatment modalities are found to be beneficial as a complementary 
therapy to oral hypoglycaemic drugs (Bradley et al., 2009, 2012; Oberg et al., 
2012). In naturopathy clinical practice, various treatment modalities are 
recommended, including gastro hepatic pack (GH pack). Among these, GH pack 
seems to be effective, which is evident in one study which focused on GH pack as 
an additional treatment in patients with diabetes mellitus. GH pack is a treatment 
modality in hydrotherapy that uses combination of hot and cold treatments. The hot 
and cold treatment modality has beneficial effects on tissue metabolism, blood flow, 
inflammation, edema and connective tissue extensibility.  While the underlying 
mechanism of the clinical benefits of GH pack remains to be studied, addition of 
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GH pack showed reduction in blood glucose levels in patients with diabetes 
mellitus.  
Treatments like gastro-hepatic pack (GHPK) and cold hip bath (CHB) have been 
found to be beneficial in type II diabetes mellitus. Gastro-hepatic pack helps to 
reduce FBS by increasing peripheral circulation and tissue oxygenation, and 
increasing metabolic rate. 
                                                  Table 1:  Temperature table 
S.NO TEMPERATURE º FAHRENHEIT º CELSIUS 
1.  Very Cold (Ice Application) 30-55 -1-13 
2.  Cold  55-65 13-18 
3.  Cool 65-80 18-27 
4.  Tepid 80-92 27-33 
5.  Warm (Neutral) 92-98 (92-95) 33-37 (33-35) 
6.  Hot 98-104 37-40 
7.  Very Hot Above 104 Above 40 
Gastrohepatic pack produces thermic and mechanical effect on the area or body 
surface where it is applied. Gastrohepatic pack stimulates the capacity of the muscle 
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to metabolize the blood sugar level and increases the circulation of blood 
throughout the body(Nair, Saxena, Devi, Chawla, & Sood, 2016).This helps to 
reduce the blood sugar level and bring the sugar level to normal range 
In hydrotherapy, water applications are made in cold, neutral and hot 
temperatures to produce thermic and circulatory reactions in the body. Cold 
hydriatic applications are tonic by reaction and used in eliminative and constructive 
phases. Hot applications, though atonic by reaction, are helpful in mitigating aches, 
pains and relieve internal congestions. Hydrotherapy is applied in the form of packs, 
steam baths, sitz bath, head or foot baths, bandages (wet or dry), fomentations and 
poultices and rubbings and water potations. 
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2. REVIEW OF LITERATURE 
3.1 DIABETES MELLITUS 
Diabetes mellitus comprises of a group of heterogeneous disorders, which have 
variation in the degrees of peripheral insulin resistance that leads to 
hyperglycaemia. Early symptoms of hyperglycaemia are polydipsia, polyphagia, 
urea and blurred vision. Later complications of hyperglycaemia occur in blood, 
vascular disease, peripheral neuropathy, nephropathy and predisposition to 
infection. 
3.2 DEFINITION 
Diabetes mellitus is a syndrome with disordered metabolism and inappropriate 
hyperglycaemia due to either a deficiency of insulin secretion or a combination of 
insulin resistance and inadequate insulin secretion to compensate.  
 
3.3 ETIOLOGY 
Type 2 diabetes mellitus (T2DM) is the most common type of diabetes. It   is 
characterized by insulin resistance. There is progressive failure of beta cells’ insulin 
secretary capacity. This is due to the defects in the action of insulin on its target 
tissues (muscle, liver, and fat). Most patients are obese, in India and most T2DM 
patients have body mass index (BMI), with increased visceral fat. Impaired insulin 
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secretion, insulin resistance, excessive hepatic glucose production, abnormal fat 
metabolism are the main characteristic features of type 2 diabetes mellitus. In the 
early stages, despite insulin resistance, glucose tolerance remains near-normal. This 
is because of the compensatory increase in insulin output by the pancreatic beta 
cells. With the simultaneous progression of insulin resistance and compensatory 
hyperinsulinemia, the pancreatic islets are incapable to endure the hyperinsulinemia 
state. 
 
Figure 2: Schematic representation of aetiology of diabetes mellitus 
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This leads to the development of impaired glucose tolerance, characterized by 
elevations in postprandial glucose. An additional deterioration in insulin secretion 
and an increase in hepatic glucose production results in overt diabetes with fasting 
hyperglycemia. Eventually, beta cell failure may follow. 
3.4 CLASSIFICATION OF DIABETES MELLIUS 
Table 2: Etiologic Classification of Diabetes Mellitus. Adapted from WHO 
and ADA 
I. type 1Diabetes mellitus  
A. Autoimmune 
B. Idiopathic 
II. type 2 Diabetes mellitus  
Ranges from relative insulin deficiency to 
disorders  
of insulin secretion and insulin resistance 
III. Other specific types of diabetes 
mellitus 
A. Genetic defects in β-cell function 
1. Chromosome 12, HNF-1α (MODY 3) 
2. Chromosome 7, glycosidase (MODY 2) 
3. Chromosome 20, HNF-4α (MODY 1) 
4. Mitochondrial DNA 
3. Nicotinic acid 
4. Glucocorticoids 
5. Thyroid hormones 
6. Diazoxide 
7. β-adrenergic agonists 
8. Tiazides 
9. Dilantin 
10. α interferon 
ii. Infections 
1. Congenital rubeola 
2. Cytomegalovirus 
iii. Infrequent forms of 
autoimmune diabetes 
1. Stiff-man syndrome) 
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5. Monogenic diabetes  
B. Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipotrophic diabetes 
C. Disease of the exocrine pancreas 
1. Pancreatitis 
2. Pancreatectomy/trauma 
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalcificpancreatopathy 
D. Endocrinopathies 
1. Acromegaly 
2. Cushing syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
i. Pharmacologically or chemically induced                            
2. Antibodies against insulin 
receptors 
iv. Other syndromes 
occasionally associated with 
diabetes 
1. Down syndrome 
2. Klinefelter syndrome 
3. Turner syndrome 
4. Wolfram syndrome 
5. Friedreich ataxia 
6. Huntington’s chorea 
7. Lawrence-Moon-Biedel 
syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader-Willi syndrome 
IV. Gestational diabetes 
mellitus 
Occurs in mostly in women 
during gestation. 
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1. Vacor 
2. Pentamidine 
 
3.4.1 TYPE I DIABETES 
Autoimmune pancreatic beta-cell destruction leads to absence of insulin 
production.In type 1 diabetes mellitus (previously called juvenile-onset or insulin-
dependent), of the autoimmune pancreatic beta-cell destruction is triggered by an 
environmental exposure in genetically susceptible people causing absence in the 
insulin production.. Destruction progresses over months or years. This occurs until 
beta-cell mass decreases to a level that insulin concentration level is no longer 
sufficient to control plasma glucose levels.  
Type 1 DM generally develops during childhood or adolescence. Recently it 
was diagnosed to occur before the age of 30. It can also develop in adults (latent 
autoimmune diabetes of adulthood). Some cases of type 1 DM, mostly in non 
white populations, do not appear to be autoimmune in nature and it is considered 
idiopathic.  
Type 1 occurs for < 10% of all cases of DM. The pathogenesis of the 
autoimmune beta-cell destruction happens due to the interactions between 
susceptibility genes, autoantigens, and environmental factors. 
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SUSCEPTIBILITY GENES: 
Susceptibility genes include those within the major histocompatibility complex 
(MHC)—mainly HLA-DR3,DQB1*0201 and HLA-DR4,DQB1*0302.They are 
present in > 90% of patients with type 1 diabetes mellitus—and those outside the 
MHC, which seem to regulate insulin production and processing and confer risk 
of diabetes mellitus in concert with MHC genes. Susceptibility genes are more 
common among some populations than among others and explain the higher 
prevalence of type 1 DM in some ethnic groups (Scandinavians, Sardinians). 
AUTOANTIGENS: 
Autoantigens include glutamic acid decarboxylase, insulin, proinsulin, 
insulinoma-associated protein, zinc transporter ZnT8, and other proteins in beta 
cells. These proteins are exposed or released during normal beta-cell turnover or 
during beta-cell injury (eg, due to infection), or when activating primarily a T 
cell‒mediated immune response resulting in beta-cell destruction (insulitis). 
Alpha cells which secretes glucagon remain unharmed. Antibodies to 
autoantigens, can be detected in the serum. These antibodies are responsible for 
the (not a cause of) beta-cell destruction. 
EVNIRONMENTAL  FACTORS: 
Several viruses (including coxsackievirus, rubella virus, cytomegalovirus, 
Epstein-Barr virus, and retroviruses) are linked to the onset of type 1 DM. Viruses 
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may infect and destroy beta cells directly. They may destruct the beta-cells 
indirectly by exposing autoantigens, activating autoreactive lymphocytes, 
mimicking molecular sequences of autoantigens which stimulate an immune 
response (molecular mimicry), or other mechanisms. 
DIET: 
Diet also may be one of the factor. Exposure of infants to dairy products 
(especially cow’s milk and the milk protein beta casein), low vitamin D 
consumption and high nitrates in drinking water have increased the risk of type 1 
DM. Islet cell autoantibody production increases in Early (< 4 mo) or late (> 7 
mo) exposure to gluten and cereals. The Mechanisms of these associations are 
unclear. 
3.4.2  TYPE II DIABETES 
 Resistance to insulin 
 In type 2 diabetes mellitus (previously called adult-onset or non– insulin-
dependent), insulin secretion is not sufficient as patients have developed 
resistance to insulin. An inability to suppress hepatic glucose production occur 
due to Hepatic insulin resistance. Due to this peripheral glucose uptake impairs 
because of peripheral insulin resistance. This combination leads to rise in fasting 
and postprandial hyperglycaemia. Often insulin levels are very high, especially 
early in the disease. Insulin production may fall later, further exacerbating 
hyperglycaemia. The disease generally develops in adults. The disease and more 
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common with increasing age. About one third of the adults above the age 65 have 
impaired glucose tolerance. Plasma glucose levels reach higher levels in older 
adults after eating than in younger adults. This happens especially after taking 
meals with high carbohydrate.  
Because of the increased accumulation of visceral and abdominal fat and 
decreased muscle mass, glucose levels take longer to return to normal. 
    Type 2 DM is becoming increasingly common among children due to obesity 
in children. Over 90% of adults with DM have type 2 disease. There is evidence 
of the high prevalence of the disease within ethnic groups (especially American 
Indians, Hispanics, and Asians) and in relatives of people with the disease, which 
is seen through clear genetic determinants. Though several genetic 
polymorphisms have been identified, no single gene responsible for the most 
common forms of type 2 DM has been identified over the past several years. 
3.5   SYMPTOMS 
Symptoms of type 1 diabetes will start suddenly, within weeks whereas the 
symptoms of type 2 diabetes will develop slowly after several years. This is because 
in type 2 diabetes the symptoms might be mild and the person might not notice 
them. Symptoms might be absent in many people with type 2 diabetes.   
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Figure 3: Schematic representation of main symptoms of diabetes mellitus
 
Until the occurrence of diabetes-related health problems in some people, like 
blurred vision or heart trouble, the person is unaware of the presence of diabetes. 
Symptoms of diabetes include 
 increased thirst and urination 
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 increased hunger 
 fatigue 
 blurred vision 
 numbness or tingling in the feet or hands 
 sores that do not heal 
 unexplained weight loss 
 3.6 MAJOR RISK FACTORS 
The combination of risk factors like genes and lifestyle lead to the Development 
of type 2 diabetes.  Risk factors such as family history, age, or ethnicity can’t be 
changed whereas the lifestyle changes can be done through changes in eating habit, 
physical activity, and weight. These lifestyle changes can change or reduce the 
development of type 2 diabetes(Mohan & Pradeepa, 2009). Taking action on the 
following factors can change delay or prevent the occurrence of type 2 diabetes. 
People are more likely to develop type 2 diabetes if they 
 are overweight or obese 
 are age 45 or older 
 have a family history of diabetes 
 are African American, Alaska Native, American Indian, Asian American, 
Hispanic/Latino, Native Hawaiian, or Pacific Islander 
 have high blood pressure 
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 have a low level of HDL (“good”) cholesterol, or a high level of triglycerides 
 have a history of gestational diabetes or gave birth to a baby weighing 9 pounds 
or    more. 
 are not physically active 
 have a history of heart disease or stroke 
 have depression  
 have polycystic ovary syndrome  
 have acanthosis nigricans—dark, thick, and velvety skin around the neck or 
armpits 
3.7 GENETIC INFLUENCES 
THE ROLE OF GENETICS IN TYPE 2 DIABETES 
Type 2 diabetes is caused by both genetic and environmental factors. Scientists 
have revealed of higher diabetes risk for people who have linked to several gene 
mutations. All who carries a mutation will not get diabetes. But many people with 
diabetes are having one or more of these mutations. 
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Figure 4: Diabetes and other co-morbidities the result of a complex 
interaction of host genetics, environment and gut microbiota. The 
development of obesity, insulin resistance, type 2 diabetes and the metabolic 
syndrome in general are the consequence of a complex multidirectional 
interaction between host genetics, environment, diet and the gut microbiota. 
To separate genetic risk from environmental risk is difficult. It is often influenced 
by the family members. For example, healthy eating parents are likely to pass 
diabetes to the next generation(Mohan & Pradeepa, 2009).  
Identifying the genes responsible for type 2 diabetes Type 2 diabetes caused by 
genetic link is Studied in twins by the scientist. These studies complicated that the 
environmental factors also influence and affects type 2 diabetes risk. Type 2 
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diabetes is affected by many mutations up to date. The contribution of every gene 
is generally small. Every additional mutation will increase the risk. 
In general, mutations in any gene that involves in controlling glucose level will 
increase the risk of type 2 diabetes.  
These include genes that control: 
 the production of glucose 
 the production and regulation of insulin 
 how glucose levels are sensed in the body 
Genes associated with type 2 diabetes risk include: 
 TCF7L2, affects insulin secretion and glucose production 
 ABCC8, helps regulate insulin 
 CAPN10, is associated with type 2 diabetes risk in Mexican-Americans 
 GLUT2, helps move glucose into the pancreas 
 GCGR, a glucagon hormone involved in glucose regulation  
Genetic testing for type 2 diabetes: 
There are many tests to check the gene mutations associated with type 2 diabetes. 
However, the increased risk for any given mutation is small.  
Other factors that predicts the development of type 2 diabetes are: 
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 body mass index (BMI) 
 family history 
 high blood pressure 
 high triglyceride and cholesterol levels 
 a history of gestational diabetes 
 having certain ancestry, such as Hispanic, African-American, or Asian-
American ancestry 
3.8   PATHOGENESIS 
Pathogenesis is complex and incompletely understood. When insulin secretion 
can no longer compensate the insulin resistance, hyperglycaemia develops. 
Insulin resistance is its characteristic. Evidences exists for beta-cell dysfunction 
and impaired insulin secretion in people with type 2 DM and those at risk of it. It 
also includes the impaired first-phase insulin secretion due to IV glucose infusion, 
a loss of normally pulsatile insulin secretion, an increase in proinsulin secretion 
signalling, impaired insulin processing, and an accumulation of is let amyloid 
polypeptide (a protein normally secreted with insulin). High glucose levels 
desensitize beta cells and cause beta-cell dysfunction (glucose toxicity), or both 
and the insulin secretion is impaired by Hyperglycaemia. In the presence 
of insulin resistance it takes years to develop these changes. 
Beta cells secrete the hormone insulin, which are located within clusters of 
cells in the pancreas called the islets of Langerhans. Insulin’s role in the body is to 
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trigger cells to take up glucose so that the cells can use this energy-yielding sugar. 
Patients with diabetes may have dysfunctional beta cells, resulting in decreased 
insulin secretion, or their muscle and adipose cells may be resistant to the effects 
of insulin, resulting in a decreased ability of these cells to take up and metabolize 
glucose. In both cases, the levels of glucose in the blood increases causing 
hyperglycaemia (high blood sugar). 
 
Figure 5: Representative diagram of pathogenesis of diabetes mellitus 
 
As glucose accumulates in the blood, excess levels of this sugar are excreted in 
the urine. Because of greater amounts of glucose in the urine, more water is excreted 
with it, causing an increase in urinary volume and frequency of urination as well as 
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thirst. (The name diabetes ellitus refers to these symptoms: diabetes, from the 
Greek diabainein, meaning “to pass through,” describes the copious urination, 
and mellitus, from the Latin meaning “sweetened with honey,” refers to sugar in the 
urine.) Other symptoms of diabetes include itching, hunger, weight loss, and 
weakness. 
The islets of Langerhans are responsible for the endocrine function of the 
pancreas. Each islet contains beta, alpha, and delta cells that are responsible for the 
secretion of pancreatic hormones. Beta cells secrete insulin, a well-characterized 
hormone that plays an important role in regulating glucose metabolism. 
There are two major forms of the diabetes. Type 1 diabetes, also referred to as 
insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes. It usually 
occurs in childhood. Type 2 diabetes, also called as non-insulin-dependent diabetes 
mellitus (NIDDM) or adult-onset diabetes. It usually occurs after 40 years of age 
and becomes more common as the age increases. 
3.8.1 TYPE I DIABETES MELLITUS 
Type 1 diabetes is usually caused by autoimmune destruction of the islets of 
Langerhans in the pancreas. There are serum antibodies to the components of the 
islets of Langerhans in type I diabetes. It includes the antibodies to insulin also. 
There is decrease in insulin secretion due to the presence of antibodies and these 
antibodies are often present from several years before the onset of diabetes. There 
is genetic variations in association with the human leukocyte antigen(HLA) 
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complex in some patients with type 1 diabetes. This involves in presenting the 
antigens to immune cells which then initiates the production of antibodies that 
attack the body’s own cells (autoantibodies).  
Figure 6: Representative diagram of pathogenesis of type 1 diabetes mellitus 
But the actual destruction of the islets of Langerhans is mostly caused by immune 
cells sensitized in some way to the components of islet tissue other than the 
production of autoantibodies. About 2 to 5 percent of children whose parents, either 
father or mother with type 1 diabetes will also develop type 1 diabetes. 
24 
 
3.8.2 TYPE II DIABETES MELLITUS 
Figure 7: Representative diagram of pathogenesis of type 2 diabetes mellitus 
Type 2 diabetes is more common than type 1 diabetes. It accounts for about 90 
percent of all cases. The frequency of type 2 diabetes is increasing throughout the 
world and varies greatly within and between countries. It can also occur in 
children and adolescents. But Most patients with type 2 diabetes are adults, mostly 
older adults. There is a strong genetic association in type 2 diabetes than to type 1 
diabetes. For example, both identical twins develop type 2 diabetes than from both 
developing type 1 diabetes. About 7 to 14 percent of people whose mother or 
father has type 2 diabetes will also develop type 2 diabetes; this estimation 
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increases from 14 percent to 45 percent if both parents are affected. In India it is 
estimated that about half of the adult Indian population has type 2 diabetes, while 
in the entire United States it is estimated that about 10 percent of the population 
has type 2 diabetes. Many patients with type 2 diabetes are asymptomatic. They 
are often diagnosed with type 2 diabetes when routine examinations show high 
blood glucose concentrations. In some patients the symptoms associated with 
diabetes is present for long term which leads to a diagnosis of type 2 diabetes. In 
few patients present the symptoms of hyperglycaemia is present for months or 
with the sudden onset of symptoms of very severe hyperglycaemia and vascular 
collapse. 
Obesity and weight gain are important determinants of insulin resistance in 
type 2 DM. They also reflect diet, exercise, and lifestyle though they have some 
genetic determinants. There is  impaired insulin-stimulated glucose transport and 
muscle glycogen synthase activity due to the increase in plasma levels of free fatty 
acids . This is due to the inability to suppress lipolysis in adipose tissue. Adipose 
tissue releases multiple factors (adipocytokines), favourably (adiponectin) and 
adversely (tumor necrosis factor-alpha, IL-6, leptin, resistin) and function as an 
endocrine organ. This influences glucose metabolism. Intrauterine growth 
restriction and low birth weight also is associated with insulin resistance in later 
life. This reflects the adverse prenatal environmental influences on glucose 
metabolism. 
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3.8.3 MISCELLANEOUS TYPES OF DIABETES 
Miscellaneous causes of diabetes mellitus of small proportion of cases include 
genetic defects which affects the beta-cell function, insulin action, and 
mitochondrial DNA (eg, maturity-onset diabetes of youth);diseases of pancreas 
(eg, cystic fibrosis, pancreatitis, hemochromatosis, pancreatectomy); 
endocrinopathies (eg, Cushing syndrome, acromegaly); toxins (eg, the rodenticide 
pyriminyl ); and drug-induced diabetes. These are mostly due to glucocorticoids, 
beta-blockers, protease inhibitors, and therapeutic doses of niacin. In all women, 
there is insulin resistance during pregnancy, but only a few develop gestational 
diabetes. 
3.9 INSULIN RESISTANCE 
When the cells in the muscles, body fat and liver start to resist or ignore the 
function of the hormone insulin it is insulin resistance. The function of insulin is to 
send signals to grab glucose out of the bloodstream and send it into the cells. 
Glucose, is the main source of energy for the body which is in the form of blood 
sugar. Grains, fruit, vegetables, dairy products, and drinks that bring break down 
into carbohydrates are the sources of glucose. When insulin resistance occurs, more 
insulin is produced by the body to fight against insulin resistance. The beta cells in 
the pancreas work hard for months to years to make insulin get worn out and so 
they cannot keep pace with the demand for more and more insulin. When insulin 
resistance increases automatically the blood sugar level rises and causes prediabetes 
27 
 
or type 2 diabetes. It may also lead to non-alcoholic fatty liver disease (NAFLD), 
which is one of the growing problems that is associated with insulin resistance. This 
will increase the risk for liver damage and heart disease.  
 
Figure 8: Summary of mechanisms that lead to insulin resistance in heart failure 
or in the metabolic syndrome. Signaling events in skeletal muscle, liver and adipose 
tissue. 
Signs and Symptoms of Insulin Resistance 
Insulin resistance is usually aggravated by a combination of factors 
linked to weight, age, genetics, being sedentary and smoking. 
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 A large waist 
The best way to tell whether the person is at risk for insulin resistance is 
by measuring the waist. A waist that measures 35 inches or more for women, 40 
or more for men are more prone for insulin resistance. In addition to a large waist, 
if there is three or more of the following, then the person is likely to have 
metabolic syndrome, which creates insulin resistance. 
 High triglycerides 
Those having cholesterol levels of 150 or higher.  
 Low HDLs 
If the Low-density lipoprotein level is below 50 for women and 40 or men 
– or taking medication to raise low high-density lipoprotein (HDL) levels. 
 High blood pressure.  
If the blood pressure reading is of 130/85 mmHg or higher, or if taking 
medication to control high blood pressure 
 High blood sugar 
If the blood sugar level is of 100-125 mg/dl (the prediabetes range) or 
over 125 (diabetes). 
 High fasting blood sugar  
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If the person is on medicine to treat high blood sugar. Mild high blood 
sugar may be an early sign of diabetes. 
 Dark skin patches 
There may be visible skin changes in case of severe insulin resistance. 
This is represented by patches of darkened skin on the back of the neck or on 
elbows, knees, knuckles or armpits. This discoloration is called acanthosis 
nigricans. There is high risk of cardiovascular disease in people with insulin 
resistance, prediabetes and type 2 diabetes. According to the International 
Diabetes Federation insulin resistance doubles the risk for heart attack and 
stroke – and triples the risk for heart attack or ‘brain attack’ which will be 
deadly. 
At the same time the insulin resistance and metabolic syndrome are also 
linked with higher risk for cancers of the bladder, breast, colon, cervix, pancreas, 
prostate and uterus.  The reason for this is that high insulin levels early in insulin 
resistance stimulates the growth of tumors and to suppresses the body’s ability 
to protect itself by killing off malignant cells. Research has also found a strong 
association between insulin resistance and memory function decline, and 
increases the risk for Alzheimer’s disease. 
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3.10 PREVALENCE 
The explosion of diabetes in India increases the development a broad spectrum 
of irreversible complications. Mortality and morbidity rate have increased among 
the diabetic patients due to microvascular and macrovascular disease. In Type 2 
diabetes the risk of some of these complications (e.g. coronary artery disease) may 
start even before onset of diabetes sets in. Rema et al observed that the prevalence 
of diabetic retinopathy in a clinic-based study to be 34.1% in 1996. In 1999, 
Dandona et al had reported a prevalence of 22.6% of diabetic in an urban South 
Indian population. A study done in Palakkad (Kerala State) reported a higher 
prevalence of 26.8% in self-reported diabetic subjects. A recent publication from 
the Chennai Urban Rural Epidemiology Study (CURES) Eye Study showed an 
overall prevalence of 17.6% of diabetic retinopathy in an urban population. This 
shows that approximately 1 in every 5 diabetic individual, may develop diabetic 
retinopathy. A few studies, mostly clinic based have looked at the prevalence of 
diabetic nephropathy in India. But most of these are clinic-based reports. In 2007, 
Unnikrishnan et al showed that prevalence of overt nephropathy was 6 2.2% and 
that of microalbuminuria was 26.9% among the Chennai population. The 
prevalence of neuropathy in urban population was estimated to be 26.1% in, a 
population-based data from our CURES group very recently. A study done in the 
year 2006, showed that foot ulcers and rates of amputations were more common 
among diabetic subjects in the rural area compared to their urban 
counterparts(Mohan & Pradeepa, 2009). 
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3.11.  COMPLICATIONS OF DIABETES MELLITUS 
3.11.1 Hyperglycemia 
High glucose concentrations will cause injury to a large number of organs and 
tissues. Most cells can adapt the rate of intracellular glucose transport during the 
condition with high glucose level concentration. They can protect them from the 
negative effect of high glucose levels in the intracellular. In contrast, other cells, 
such as β cells, neuronal, and endothelial cells, are unable to activate this control of 
glucose afflux and they equilibrate their intracellular glucose level to the 
extracellular concentrations, and therefore are more susceptible to the effect of 
hyperglycaemia. Hyperglycaemia can cause acute and chronic complications, 
which represent important determinants of morbidity and mortality, and have a 
negative impact on the prognosis of people affected by this disease 
Acute complications of hyperglycaemia: 
Serious acute complications, such as diabetic ketoacidosis (DKA) and 
hyperosmolar hyperglycaemic state (HHS) can occur due to hyperglycaemia in 
endocrine emergencies. There is excessive counter-regulatory action of hormones 
like (glucagon, growth hormone, cortisol, catecholamines) in relation with absolute 
or relative insulin deficiency. This leads to Ketoacidosis and hyperosmolar 
hyperglycaemic state. DKA is more common in young people with diabetes, 
whereas HHS is more common among older patients. But DKA and HHS can be 
present in people of all age. It was assumed that only patients with T1D were at risk 
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of developing DKA and patients with T2D were at the risk of developing HHS for 
a long time. But from recent studies it is clear that both conditions can occur in both 
T1D or T2D. In some people there is some overlap between these two conditions 
sometimes. There may be mild or moderate acidosis in some patients with HHS 
when there is severe dehydration. This is mainly due to hypoperfusion/lactic 
acidosis. Sometimes some patients with T1D may also have some features of HHS, 
such as severe hyperglycemia. 
3.11.2   Hypoglycaemia 
Hypoglycaemia, also referred to as insulin reaction or insulin shock, is defined 
as abnormally low glucose in the blood (low blood sugar), usually below 70 mg/dL. 
The condition is usually associated with several symptoms, including shakiness, 
nervousness, sweating, chills and clamminess, dizziness, hunger and nausea, 
confusion, weakness, sleepiness, seizures, and losing consciousness. Severe 
hypoglycaemia can cause accidents, injuries, coma, and may even prove fatal 
(Davidson, 2010). Recent studies have associated severe hypoglycaemia as a risk 
factor for dementia, falls, fractures, and heart attacks (Harrison, n.d.). The simplest 
solution under hypoglycaemic conditions is to provide a sugar source to the patient. 
However, managing the condition can prove especially challenging in individuals 
who are hypoglycaemic without any evident symptoms, defined as hypoglycaemia 
unawareness. Patients suffering from hypoglycaemia unawareness would be 
difficult to wake from sleep if they do get hypoglycaemic at night. This condition 
is most commonly observed in individuals who experience frequent episodes of 
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hypoglycaemia, among chronic diabetics, or in those with tightly controlled 
diabetes. 
3.11.3   Diabetic ketoacidosis: 
DKA is an acute life-threatening complication of diabetes, characterized by the 
triad of hyperglycaemia (>250 mg/dl), metabolic acidosis (decreased pH and 
bicarbonates), and increased total body ketone concentration. DKA represents the 
initial manifestation of T1D in 13–80% of cases and it can also occur in up to 25% 
of cases of T2D at onset. In addition, DKA is a common complication in patients 
with known diabetes, where it may be the consequence of poor compliance with 
insulin treatment, acute illness, or malfunction of diabetes care equipment (Gh, 
Nithin, & G, 2014). Mortality associated with DKA is predominantly related to the 
occurrence of cerebral edema, which occurs in 0.3–1% of patients, whereas only a 
minority of deaths in DKA is due to other causes. 
3.11.4   Hyperosmolar hyperglycaemic state 
HHS is the most serious acute hyperglycaemic emergency in patients with T2D. 
Diagnostic criteria for this condition are glucose level >600 mg/dl and increased 
effective plasma osmolality >320 mOsm/kg, in the absence of ketoacidosis (Gh et 
al., 2014). The incidence of HHS is estimated to be < 1% of hospital admissions of 
patients with diabetes and the associated mortality is 10–20%. There are no good 
data from randomized studies on the best management of HHS, which has been 
mainly extrapolated from studies of patients with DKA. In HHS, the goals of initial 
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fluid therapy are to expand the intra- and extravascular volume, restore normal renal 
perfusion, and promote a gradual decline in serum sodium concentration and 
osmolality 
3.11.5 Diabetic Coma 
Coma is relatively rare in diagnosed diabetes but it is very important to be aware 
of the situations that increase risk of coma. The main causes of coma occurring in 
people with diabetes are as a result of very low or very high blood glucose levels. 
There are three most common causes of coma in diabetic people: 
 Severe hypoglycaemia 
 Diabetic ketoacidosis 
 Hyperglycaemic hyperosmolar state 
Diabetic comas occur when a person doesn’t take steps to regulate or balance the  
blood sugar level when it is too high or too low. Blood sugar levels drop when the  
person don’t eat properly at time or when more insulin is taken. Blood sugar level  
may rise when a dose of insulin or other diabetes medication is missed, when diet  
plan is not followed properly, or when there is lack of exercise than the usual. In people 
with diabetes blood sugar may rise during infections, hormone imbalances, and severe 
illnesses. High blood sugar usually comes on to normal slowly than low blood sugar. 
 Diabetic comas can occur due to some of other few factors like: 
 When an insulin pump doesn’t work properly 
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 Trauma, surgery, or another health problem, such as heart failure 
 When meals are skipped or not insulin is not taken 
 On taking alcohol or illegal drugs. 
Multiple, primarily vascular complications may result due to Poorly controlled  
Hyperglycaemia. This affect small vessels (microvascular), large vessels  
(macrovascular), or both.  
 
Figure 9: Representative diagram of major microvascular and macrovascular 
complications of diabetes mellitus 
3.11.6   Microvascular disease  
Here underlie 3 common manifestations of diabetes mellitus: 
 Retinopathy 
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 Nephropathy 
 Neuropathy 
Microvascular disease may also impair skin healing, that even minor breaks in 
skin integrity can develop into deeper ulcers and easily become infected, 
particularly in the lower extremities. Control of plasma glucose can help in 
preventing or delaying many such complications. But once established the 
condition may not be reversed. 
3.11.7 Macrovascular disease  
It involves atherosclerosis of large vessels, which can lead to 
 Angina pectoris and myocardial infarction 
 Transient ischemic attacks and strokes 
 Peripheral arterial disease 
3.11.8   Immune dysfunction  
It is also one of the major complications and develops from the direct effects 
of hyperglycaemia on cellular immunity. Bacterial and fungal infections are more 
prone for the patients with diabetes mellitus. 
3.12 DIAGNOSTIC CRITERIA: 
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 
revised the diagnostic criteria. Two replicate fasting levels that exceed 126 mg/dl 
(>7 mmol/L) are diagnostic of diabetes in the absence of symptoms. Definition of 
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the cut-point for normal fasting blood glucose levels was dropped from 110 mg/dl 
to 100 mg/dl, meaning that a value of 100 mg/dl or above would lead to a diagnosis 
of impaired fasting glucose (IFG). Persons with IFG levels (FPG= 100-125 mg/dl 
(5.66.9 mmol/l) and/or with impaired glucose tolerance test (IGT) (2 hour post-load 
glucose 140-199 mg/dl (78.8 mmol/L-11.1 mmol/L) are at risk of diabetes and 
should be observed periodically to detect hyperglycaemic progression. Replicate, 
two-hour glycaemic responses >200 mg/dl (>11.1 mmol/L) after a standard oral 
glucose tolerance test also indicates diabetes. However, this stage is often reached 
before the fasting glucose levels rise in T2DM. Indeed, post-prandial 
hyperglycaemia may precede fasting hyperglycaemia by months to years. Thus, the 
reliance on only fasting glucose levels as recommended by the ADA expert 
committee is generally useful for identification of impending T1D but not for T2D. 
The ADA has suggested that the measurement of HbA1c levels can be used in 
clinical practice for the diagnosis of diabetes more recently. 
               Table 3: The American Diabetes Association Diagnostic Guidelines 
Glucose Level ADA Evaluation 
Normal Fasting plasma glucose (FPG) <100 mg/dL (5.6 
mmol/L) 
Impaired Fasting 
Glucose (IFG) 
Fasting plasma glucose (FPG) >100 (5.6 mmol/L) but 
<126 mg/dL (7.0 mmol/L) 
38 
 
Impaired Glucose 
Tolerance (IGT) 
Two-hour plasma glucose level of >140 mg/dl (7.8 
mmol/L) but <200 mg/dl (11.1 mmol/L) 
Diabetes mellitus FPG =126 mg/dL (7.0 mmol/L) or 2 hour plasma 
glucose ≥200 mg/dl (11.1 mmol/L) during an oral 
glucose tolerance test (OGTT*) in the absence of 
symptoms or a random plasma glucose ≥200 mg/dl 
(11.1 mmol/L) with symptoms of polyuria, and weight 
loss. 
HbA1C HbA1C ≥6.5%. The test should be performed in a 
laboratory using a method that is National 
Glycohemoglobin Standardization Program (NGSP) 
certified and standardized to the Diabetes Control and 
Complications Trial (DCCT) assay 
 
 
* The OGTT should be performed as described by the World Health Organization  
(1.75 gm/kg up to 75 gm, using a glucose load containing anhydrous glucose  
dissolved in water). 
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3.13 NATUROPATHY IN DIABETES MELLITUS MANAGEMENT: 
The use of naturopathy treatment modalities is comparatively common among 
patients with type 2 diabetes mellitus (T2DM) around the world (Al-Eidi et al., 
2016; D. Garrow & Egede, 2006; Donald Garrow & Egede, 2006; Pandey, Tripathi, 
Pandey, Srivatava, & Goswami, 2011; Ramachandran et al., 2001). Studies have 
shown the beneficial role of naturopathy treatments in improving the glycaemic 
control in diabetes mellitus patients when used as an adjunctive with to 
pharmacotherapy.  
 
Figure 10: The American Diabetes Association Diagnostic Guidelines 
The role of diet and physical activity in the form of integrated yoga therapy along 
with naturopathy treatments were also beneficial in bringing out improvements in 
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various favourable outcomes related to diabetes mellitus (Mehr, Surwit, & Mehr, 
2014; Mooventhan & Shetty, 2015). Studies also show the role of naturopathy 
treatments in aiding the patients in reducing the medications (Bairy et al., 2016). 
Nutritional behavioural modification by the naturopathic-physician delivered 
nutritional education has also proven to be of significant important in treating 
diabetic patients (Erica B. Oberg, ND MPH1,*, Ryan D. Bradley, ND MPH1, Jason 
Allen, ND MPH1, and Megan A. McCrory, 2011). Naturopathy treatments were 
shown to be effective in improving the health status of the patients by shifting the 
vitals favourably like B.P, weight, BMI, lipid profile-cholesterol, triglycerides and 
HDL, glycemic status - blood sugar fasting, post prandial and HBA1C. Its also 
effective in reducing the oxidative stress (glutathione peroxidase and total 
antioxidative capacity) and altering the hormonal status (adiponectin, insulin 
resistance, insulin sensitivity and beta cell function) (Nair, 2016; Nair, Saxena, 
Chawla, Sood, & Jain, 2016).  
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1. RATIONALE 
The large body of research studies documents the presence of multisystem 
dysfunction in diabetes mellitus.  Similarly, there are also data on how various 
forms of naturopathy treatment modalities given in an integrated approach play a 
key role in the management of diabetes mellitus. Previous studies shed light on the 
beneficial effects exerted by integrated naturopathy managements. 
Unfortunately, in the literature, we were unable to find any study in which in a 
single study scenario, the impact of Gastrohepatic pack in diabetes mellitus used 
alone were evaluated.  
Therefore, the present study was carried out to test the effects of GH pack in patients 
with diabetes mellitus in comparison to naturopathy treatment modalities other than 
Gastrohepatic pack to suggest a road map for the future clinical applications in type 
II Diabetes Mellitus. 
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2. AIMS AND OBJECTIVES 
AIMS: 
To Study the Effects of Gastro-hepatic Pack in type II Diabetes Mellitus. 
 
OBJECTIVES: 
The objective of the study is to evaluate the Fasting blood sugar level and Post 
Prandial blood sugar level in type II diabetes mellitus patient before and after the 
treatment.      
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3. METHODOLOGY (MATERIALS AND METHODS) 
 After obtaining informed consent, the patient is recruited randomly through lot 
method. Among the 60 recruited subjects, 30 recruited subjects in the 
intervention group, will be given gastro-hepatic pack for a duration of 30 minutes 
along with conventional medication. The hot water bag (98 to 104 degree F) is 
kept on the abdominal region, covering the epigastric region, left and right 
hypogastric region, left and right lumbar region and umbilical region. The ice 
bag (55 to 65 degree F) covers the region of lumbar vertebrae L2, L3, L4 and 
L5.  
 
    Figure 11: Gastro hepatic pack 
 
 The treatment is administered in supine lying position, where the hot fomentation 
bag is kept over the abdominal region and then the ice bag on lower back region. 
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The patients are then covered with cotton cloth and wrapped with woollen 
blanket.  
 30 patients in the control group will undergo regular Naturopathic and Yogic 
interventions along with the conventional medication. 
TEMPERATURE: 
 Ice bag (55 to 65 degree  F) 
 Hot water bag (98 to 104 degree F) 
Inclusion Criteria 
1) Patients with Type II Diabetes Mellitus who is taking conventional medication. 
2) Age group 40 to 60 years 
3) Both Gender 
Exclusion Criteria 
1) Patient with Cardiovascular disorder 
2) Diabetic Nephropathy 
3) Diabetic Retinopathy 
4) All types of Hernias 
5) Spinal Injuries and Spinal Surgery 
6) Nervous Disorders 
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STUDY DESIGN: 
Figure 12: Flowchart of study design 
60 Patients (30 in Control group and 30 in Intervention Group). The patients were 
screened and the patients eligible for the study were selected from the Out Patient 
department of Government Yoga and Naturopathy Medical College Hospital.85 
Eligible patients were selected and randomized through lot method.35 patients were 
selected for the intervention group and 35 patients were selected for the control 
group. The patients were explained about the study. 
After receiving the consent, the baseline data like Name, age, sex, height, weight, 
FBS, PPBS, Pulse rate, Heart rate, blood pressure were taken for the patients of 
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both the intervention group and the control group. The patients in the intervention 
group were given only GHPK whereas the patients in the control group were given 
naturopathy treatment other than GHPK. 
The treatments were given for the patients of both group for 4 weeks. After 4th 
week of intervention, post interventional data like, FBS, PPBS, height, weight, 
pulse rate, heart rate and blood pressure were taken for analysis. 
 
 
 
Figure 13: Representative diagram of study design 
The baseline assessment of the variables was done for the patients immediately 
following the recruitment (within 3 days). The patients in the GH pack group received 
gastro-hepatic pack for a duration of 30 minutes daily. The patients in the control group 
received naturopathy treatments daily exclusive of GH pack. Following the prescribed 
intervention period of 4 weeks in each patient, post-intervention assessment of the 
variables was repeated.  
 
Baseline Post-intervention 
4  Weeks 
wwwww
weeks 
Intervention 
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PROCEDURE FOR GASTRO HEPATIC PACK: 
Materials required for GH Pack are given in the following figures. 
Figure 14: Material I: ICE BAG
 
 
  Figure 15: Material II : HOT FOMENTATION BAG 
 
 Ice cubes are filled in 
this bag and placed in the 
lower back of the patient. 
 Temperature of the ice 
bag should be 55 to 65 
degree F 
 
 Hot fomentation should 
be placed over the 
abdominal region of the 
patient. 
 Temperature of hot 
water bag should be 98 
to104 degree F 
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Figure 16: Material III : WOOLLEN CLOTH 
Figure 17: Material IV : COTTON CLOTH 
 
 
                                                  
 This forms the outermost 
covering of the Gastro-
hepatic pack 
 The cotton cloth is wrapped 
over the hot water bag and 
ice bag. 
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The woollen cloth is spread on the table where the patient will be made to lie for 
the treatment. A cotton cloth is spread on the woollen cloth. Ice bag is placed on the 
cotton cloth. Patient is made to lie on the ice bag. The ice bag (55 to 65 degree  F) covers 
the region of lumbar vertebrae L2, L3, L4 and L5. The hot water bag (98 to 104 degree 
F) is kept on the abdominal region, covering the epigastric region, left and right 
hypogastric region, left and right lumbar region and umbilical region. The patient is 
then covered with cotton cloth and wrapped with woollen blanket. 
Figure 18: Pictorial illustration of GH Pack procedure 
Step1:
 
 
 
 
The woollen cloth is spread 
on the table where the 
patient will be made to lie 
for the treatment. A cotton 
cloth is spread on the 
woollen cloth. Ice bag is 
placed on the cotton cloth. 
Patient is made to lie on 
the ice bag. 
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Step 2: 
 
Step 3: 
 
 
  
The patient is then covered 
with cotton cloth. 
 
The hot water bag (98 to 
104 degree F) is kept on 
the abdominal region, 
covering the epigastric 
region, left and right 
hypogastric region, left and 
right lumbar region and 
umbilical region. 
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Step 4: 
 
The treatment is administered in supine lying position, where the hot fomentation 
bag is kept over the abdominal region and then the ice bag on lower back region. 
The patient will be given gastro-hepatic pack for a duration of 30 minutes. 
Physiological Effect of GH Pack: 
During this application the blood is drained from the stomach, liver, spleen and 
pancreas and congestion is relieved. Thus, this pack influences not only the stomach 
and liver, but also the spleen and the pancreas. It is helpful in cases of Gastritis, 
liver and spleen enlargement, ulcers in the stomach, hyperacidity and inflammation 
of the pancreas. This pack is extensively used to treat Diabetes Mellitus. It is also 
used in Gastric Congestion in Indigestion, Hepatic Congestion, Splenic Congestion, 
The patient is then wrapped 
with woollen blanket. 
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Pancreatic Congestion and in Visceral Congestion of the upper abdomen. 
Gastrohepatic pack produces thermic and mechanical effect on the area or body 
surface where it is applied. Gastrohepatic pack stimulates the capacity of the muscle 
to metabolize the blood sugar level and increases the circulation of blood 
throughout the body (Nair, Saxena, Devi, et al., 2016). This helps to reduce the 
blood sugar level and bring the sugar level to normal range. 
Water applications are made in cold, neutral and hot temperatures to produce 
thermic and circulatory reactions in the body. Cold hydriatic applications are tonic 
by reaction and used in eliminative and constructive phases. Hot applications, 
though atonic by reaction, are helpful in mitigating aches, pains and relieve internal 
congestions. Gastro-hepatic pack helps to reduce FBS by increasing peripheral 
circulation and tissue oxygenation, and increasing metabolic rate. 
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Statistical analysis 
Data was recorded on a predesigned proforma and managed on an excel 
spreadsheet. Quantitative variables were tested for approximate normal distribution 
using Shapiro–Wilk normality test. In case of Gaussian data distribution, parametric 
tests were applied and for non-Gaussian distribution, appropriate non-parametric 
tests were applied. The continuous variables between the groups were compared 
using independent t-test for parametric data or Mann-Whitney test for 
nonparametric data. Between-group comparisons of categorical variables were 
performed using chi-square/Fisher’s exact test.  
Data of normally distributed parameters were expressed as the mean ± SD and 
non-parametric data are expressed as median (interquartile range) for continuous 
variables and number for categorical data, as appropriate.  
The differences between the baseline and 4th week measures were calculated to 
determine the changes in the outcome measures. Within-group change in 
continuous variables did not follow normal distribution and was evaluated using 
Wilcoxon signed-rank test. Data were analyzed using SPSS17 statistical software. 
In this study p-value less than 0.05 was considered statistically significant. 
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Figure 19: STATISTICAL ANALYSIS PLAN 
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1. RESULTS: 
Figure 20: Modified consort flow diagram of patient recruitment : 
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The patient who are eligible for the study were selected from the Out Patient 
department of Government Yoga and Naturopathy Medical College Hospital. 85 
Eligible patients were selected and randomized through lot method. 35 patients 
were selected for the intervention group and 35 patients were selected for the 
control group. The patients were explained about the study. After receiving the 
consent, the patients in the intervention group was given only GHPK whereas the 
patients in the control group were given naturopathy treatment other than GHPK. 
The patients were taking conventional therapy along with the naturopathy 
treatments. 
There was loss of follow-up of 5 patients in the control group and 5 patients in 
the interventional group due to lack of interest in continuing the treatment, moving 
to other hospital and moving out of station. Finally, follow-up of the study and 
analysis was done for 30 patients in the interventional group and 30 patients in the 
control group. 
The study was conducted in the Government Yoga and Naturopathy Medical 
College Hospital, Chennai outpatient department from November 2018 to April 
2019.  
A total of 85 Diabetes mellitus patients were screened for eligibility. Out of 85 
patients, 15 patients were excluded from the study due to reasons like lack of 
interest in research and inability to comply due to travel issues. 
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The remaining 70 patients were randomly allotted to either Gastro hepatic pack 
group or control group. In both the Gastro hepatic pack group and the control group, 
5 patients dropped out after the baseline assessments. 
Therefore, a total of 30 patients in the Gastro hepatic pack group and 30 in the 
control group completed the study.  
Comparison of baseline characteristics of study participants between two 
groups 
Baseline demographic and clinical characteristics were similar in both groups. 
Age, gender, height and weight were comparable between the groups. the median 
age of patients in the GH pack group were 57 years and those in the control group 
were 54 years. The GH pack group consisted of fourteen males and 16 females. The 
control group likewise consisted of seventeen males and thirteen females. Similarly, 
there was no significant difference in systolic blood pressure, diastolic blood 
pressure and heart rate between the groups.  
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Table 4: Comparison of baseline characteristics of study participants between 
two groups 
Variables GH pack 
group 
(n=30) 
Control 
group 
(n=30) 
p-
value 
Age, yr 57(51,60) 54(50,60) 0.62 
Gender (male), n 14 17 0.43 
Height (cm) 165(162,167) 165(160,167) 0.87 
Weight (kg) 70(62,82) 82(67,86) 0.12 
Systolic blood pressure 
(mmHg)# 
125.03±8.82 127.33±7.24 0.27 
Diastolic blood pressure 
(mmHg) 
83.40±4.43 83±4.32 0.72 
Heart rate (bpm) 82.86±2.33 82.70±2.97 0.80 
The systolic blood pressure in the GH pack group was 125.03±8.82 and that in the 
control group was 127.33±7.24. The diastolic pressure in the GH pack group was 
83.40±4.43 and that in the control group was 83±4.32. Data are expressed as mean±SD 
for parametric continuous variables, Median (interquartile range) for non-parametric 
continuous variables. 
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p-Value for within-group obtained by Wilcoxon signed-rank test. p-Value for between 
group change obtained by Mann-Whitney test. p-Value for Categorical variables were 
performed using chi-square/Fisher’s exact test. 
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Figure 21: Comparison of age at baseline between the study groups: There was no 
significant difference between the Gastro hepatic pack group and the control group. 
p=0.62.
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Figure 22: Comparison of weight at baseline between the study groups: The mean 
weight of patients in the control group was higher than the mean weight of patients 
in the GH pack group. However, there was no significant difference between the 
Gastro hepatic pack group and the control group. p=0.12. 
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Figure 23: Comparison of systolic blood pressure at baseline between the study 
groups: There was no significant difference between the Gastro hepatic pack group 
and the control group. p=0.27. 
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Figure 24: Comparison of diastolic blood pressure at baseline between the study 
groups: There was no significant difference between the Gastro hepatic pack group 
and the control group. p=0.72. 
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Figure 25: Comparison of heart rate at baseline between the study groups: There 
was no significant difference between the Gastro hepatic pack group and the control 
group. p=0.80. 
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Figure 26: Comparison of fasting blood sugar at baseline between the study groups: 
There was no significant difference between the Gastro hepatic pack group and the 
control group. p=0.06. 
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Figure 27: Comparison of post prandial blood sugar at baseline between the study 
groups: There was no significant difference between the Gastro hepatic pack group 
and the control group. p=0.82. 
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Table 5: Associated risk factors in patients of DM for study groups 
Risk factors GH pack 
group 
(n=30) 
Control group 
(n=30) 
p-value 
Hypertension, n 14 15 0.79 
Dyslipidemia, n 12 16 0.30 
Smoking, n 10 8 0.57 
p-Value obtained by chi-square/Fisher’s exact test. Associated co-morbidities like 
hypertension, dyslipidemia and smoking were also comparable at baseline between 
the groups.  
The GH pack group had 14 hypertensives and 16 normotensives as compared to the 
control group with 15 hypertensives and 15 normotensives. In the GH pack group, 
12 patients were having dyslipidemia as compared to 16 patients with dyslipidemia 
in the control group. Likewise, 10 smokers and 20 non-smokers were present in the 
GH pack group. The control group consisted of 8 smokers and 22 non-smokers. 
Table 6: FBS and PPBS after 4 weeks of intervention within the groups 
Variable  Group n Assessment period Within 
group 
p-value 
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Baseline Week 4 
FBS GH 
pack 
30 140(130,160) 123(114,133) <0.0001 
Control 30 150(141,160) 136(130,147) <0.0001 
PPBS GH 
pack 
30 220(210,231) 200(188,212) <0.0001 
Control  30 220(210,243) 208(194,230) <0.0001 
Data are expressed as median (interquartile range). 
p-Value for within-group obtained by Wilcoxon signed-rank test.  
The baseline FBS in the GH pack group was 140(130,160) as compared to the 
control group with a median value of 150(141,160). This decreased significantly in 
GH pack group to 123(114,133), p<0.0001 following the intervention. Likewise, 
there was a fall noted in the control group also in the FBS to 136(130,147), 
p<0.0001. 
The baseline PPBS in the GH pack group was 220(210,231) as compared to the 
control group with a median value of 220(210,243). This decreased significantly in 
GH pack group to 200(188,212), p<0.0001 following the intervention. Likewise, 
there was a fall noted in the control group also in the PPBS to 208(194,230), 
p<0.0001. 
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Figure 28: Figure shows effect of Gastro hepatic pack and naturopathy interventions 
in fasting blood sugar within GH pack group and control group respectively. There 
was a significant reduction in FBS in GH pack group, p<0.0001. Similarly, control 
group showed a significant reduction in FBS following naturopathy intervention in 
control group, p<0.0001. p value<0.05 was considered as statistically significant. 
***represents p<0.0001. 
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Figure 29: Figure shows effect of Gastro hepatic pack and naturopathy interventions 
in post-prandial blood sugar within GH pack group and control group respectively. 
There was a significant reduction in PPBS in GH pack group, p<0.0001. Similarly, 
control group showed a significant reduction in PPBS following naturopathy 
intervention in control group, p<0.0001. p value<0.05 was considered as 
statistically significant. ***represents p<0.0001. 
Table 7: FBS and PPBS after 4 weeks of intervention between the groups 
Variable  Group 
 
 
n Assessment period Between 
group 
p-value 
Baseline Week 4 
FBS GH 
pack 
30 140(130,160) 123(114,133) 0.003 
Control 30 150(141,160) 136(130,147) 
PPBS GH 
pack 
30 220(210,231) 200(188,212) 0.08 
Control  30 220(210,243) 208(194,230) 
Data are expressed as median (interquartile range). 
p-Value for between group change obtained by Mann-Whitney test. 
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Figure 30: Figure shows effect of Gastro hepatic pack and naturopathy interventions 
in fasting blood sugar between GH pack group and control group respectively. 
There was a significant difference in the effects of both the interventions in FBS, 
p=0.003. Both the groups were comparable at the baseline. p value<0.05 was 
considered as statistically significant. ***represents p<0.0001. 
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Figure 31: Figure shows effect of Gastro hepatic pack and naturopathy interventions 
in post prandial blood sugar between GH pack group and control group 
respectively. There was a no significant difference in the effects of both the 
interventions in PPBS, p=0.08. Similarly, both the groups were comparable at the 
baseline. p value<0.05 was considered as statistically significant. ***represents 
p<0.0001. 
Table 8: Change in FBS and PPBS after 4 weeks of intervention between the 
groups 
Variable  Group n Difference at 4th week p-value 
FBS GH 
pack 
30 -11.76(-17.32,-10) 0.0003 
Control 30 -8.57(-10.95,-7.18) 
PPBS GH 
pack 
30 -9.56(-10.52,-7.40) 0.0004 
Control  30 -6.79(-7.85,-5.45) 
Data are expressed as median (interquartile range). 
p-Value for within-group obtained by Wilcoxon signed-rank test.  
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Figure 32: Figure shows that both the Gastro hepatic pack and naturopathy 
interventions cause a reduction in fasting blood sugar in the respective GH pack 
group and control group. There was a significant difference noted between the 
groups in the mean change score in the post-intervention period. The gastro-hepatic 
pack caused a higher magnitude of fall in fasting blood sugar as compared to the 
magnitude of fall noted in the control group, p=0.0003. Similarly, both the groups 
were comparable at the baseline. p value<0.05 was considered as statistically 
significant. ***represents p<0.0001. 
Mean change score is the average magnitude of difference noted in the gastro-
hepatic pack group and the control group during the post-intervention period as 
compared to the baseline. Following the intervention, a fall in fasting blood glucose 
is noted in the gastro-hepatic pack group. Similarly, a fall in the control group is 
also noted in the fasting blood glucose level. However, the magnitude of fall is 
higher in the gastro-hepatic pack group as compared to the control group. 
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Figure 33: Figure shows that both the Gastro hepatic pack and naturopathy 
interventions cause a reduction in fasting blood sugar in the respective GH pack 
group and control group. There was a significant difference noted between the 
groups in the mean change score in the post-intervention period. The gastro-hepatic 
pack caused a higher magnitude of fall in fasting blood sugar as compared to the 
magnitude of fall noted in the control group, p=0.0004. Similarly, both the groups 
were comparable at the baseline. p value<0.05 was considered as statistically 
significant. ***represents p<0.0001. 
Mean change score is the average magnitude of difference noted in the gastro-
hepatic pack group and the control group during the post-intervention period as 
compared to the baseline. Following the intervention, a fall in post-prandial blood 
glucose is noted in the gastro-hepatic pack group. Similarly, a fall in the control 
group is also noted in the post-prandial blood glucose level. However, the 
magnitude of fall is higher in the gastro-hepatic pack group as compared to the 
control group. 
71 
 
 
Summary of results 
Table 9: Overall summary of the results demonstrating the magnitude of 
change in each group following the intervention 
S.NO Indices GH pack group vs. Control group 
Magnitude of 
change in GH 
pack group 
Magnitude of 
change in 
control group 
1.  FBS   
2.  PPBS   
Our results show a fall in FBS and PPBS in both the groups following the 
intervention. However, the magnitude of reduction was higher in the GH pack group 
than the control group for both FBS and PPBS. 
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DISCUSSION  
Non-Insulin Dependent Diabetes Mellitus (NIDDM) is a complex and chronic 
disease which is increasing in prevalence in the present days. Complementary and 
Alternative Medicine (CAM) modalities are found to be effective in the 
management of NIDDM (Dunning, 2014). Naturopathic treatment modalities are 
also found to be beneficial as a complementary therapy to oral hypoglycaemic drugs 
(Dean, Kukla, Stegall, & Kudva, 2017; Nagaich & Dr., 2016). Treatments like 
gastro-hepatic pack (GHP) and cold hip bath (CHB) have been found to be 
beneficial in T2D. GHP helps to reduce FBS by increasing peripheral circulation 
and tissue oxygenation, and increasing metabolic rate. Hydrotherapy is a part of 
CAM, used in the management of NIDDM (Angermayr, Melchart, & Linde, 2010). 
GHPK is one of the hydrotherapies used in the treatment of NIDDM. The present 
study is to evaluate the efficacy Gastrohepatic pack in the treatment of patients with 
type 2 DM. There are various researches which shows that GHPK is more effective 
in the treatment type 2 DM. Hydrotherapy helps for detoxification (helps in 
elimination of waste), loosening tense muscles and assisting relaxation, enhances 
metabolic rate and digestion activity, cell hydrating, and improves skin and muscle 
tone. In addition, it also improves the immune system by its efficient functioning 
and also improves internal organs functioning by stimulating blood supply 
(Lakshmeesha D R, BNYS, Prashanth Shetty, BNYS, Ryan Bradley, ND, & R K. 
Roshni Raj Lakshmi, 2015).  
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The results of the study have shown statistically significant changes in fasting 
blood glucose levels in Gastrohepatic pack subjects (p=0.0003) and postprandial 
blood glucose levels (p=0.0004) after the intervention period. The results of present 
study suggest that both the Gastrohepatic pack and naturopathy treatments other 
than GHPK have shown significant result in FBS level and PPBS level. 
Gastrohepatic pack has shown relatively better glycaemic control as compared to 
other naturopathy treatments. A study shows that heat application on the abdomen 
produces increased peripheral circulation and increases the total haemoglobin level 
in the muscle tissue significantly. It also increases the muscle tissue oxygen 
saturation in muscle tissue in the area where heat is applied (Dinesh & R, 2014).  
The significant reduction in FBG the study may be due to increase in the 
peripheral circulation and tissue oxygen saturation levels. local cold application 
induces alterations in thermogenesis mechanism which increases the metabolic rate. 
The thermoregulatory changes stimulate the increase in blood circulation by hot 
application and ice application in the lower back. This application of GHPK 
increases the metabolism. This thermoregulatory change increases the blood supply 
to the abdominal region and increases the metabolism in the liver and other 
abdominal organs. The fasting blood glucose level is reduced by this mechanism 
  
Naturopathy treatments other than GHPK might increase the peripheral 
circulation and induce metabolism in muscle and skin tissue. This might have 
increased glucose uptake in the periphery. This may be the reason for reduction of 
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FBG with mild PPBG reduction in the present study. Various naturopathy and yoga 
treatment modalities has been shown to be effective in the management of diabetes 
and its complications(Angadi et al., 2017; Mohanty, Mooventhan, & Manjunath, 
2016). Naturopathy helps in promoting positive health, by alleviating the symptoms 
of disease by acting on the physical and mental levels (Gowda, Mohanty, Saoji, & 
Nagarathna, 2017). 
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LIMITATIONS 
In the Present study the data is collected and analysis is done for the pre and post 
data for the duration of 4 weeks. If the study is conducted for a duration of 3 months 
the result of the study might be still more significant. For this purpose, HbA1C 
value of 3 months should be taken along with other data pre and post to the study. 
This might show more significant result in both FBS level and PPBS level. 
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Future Directions: 
Our results show significant reduction in FBS and PPBS in diabetes patients 
irrespective of the GH pack group and the control group which received naturopathy 
treatments other than GH pack. Large clinical trials can be conducted in the future 
with large sample size.  
Assessment of other cardiac biomarkers following the naturopathy treatments and 
GH pack might bring about more insights into the mechanisms underlying the 
beneficial effects of naturopathy treatments in the prevention of complications and 
management of diabetes. 
 
  
77 
 
CONCLUSION 
The present study suggests that Gastrohepatic pack and Naturopathy treatments can 
play a major role in lowering the raised blood glucose levels in patients with T2 
DM. Gastrohepatic pack is relatively better for lowering the blood glucose levels as 
compared to Naturopathy treatments without GHPK. Further studies with bigger 
sample size are required for more robust conclusions. ` 
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SUMMARY 
There are many Naturopathy treatments for reducing the blood sugar level in 
type 2 diabetes mellitus. This study was conducted to know the efficacy of GHPK 
in the treatment of diabetes mellitus. There is a significant result in FBS and PPBS 
when GHPK is given along with other naturopathy treatments. This study is 
conducted to evaluate the result of GHPK when it is given separately without other 
complementary therapy. 
From this study it is evident that there is a significant result in the patients of 
both interventional group and control group. There is more significant reduction in 
the FBS and PPBS level in the GHPK group than the reduction of FBS and PPBS 
level of the control group. This study shows that there is more significant result in 
lowering the blood sugar level when GHPK is given separately. 
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                      ANNEXURE 
INFORMED CONSENT FORM 
Title of the study : To Study the Effects of Gastro-hepatic pack in  
   Type II Diabetes Mellitus 
Name of the 
Participant 
: ______________________ 
Name of the Principal 
Investigator 
: Dr S EDMIN JENITTA 
Name of the Institution : Government Yoga & Naturopathy Medical 
College & Hospital, Chennai – 600 106 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been 
answered. I am over 18 years of age and, exercising my free power of choice, 
hereby give my consent to be included as a participant in the study titled, “To 
Study the Effects of Gastro-hepatic pack in the Patients with Type II Diabetes 
Mellitus”. 
1. I have read and understood this consent form and the information provided to 
me. 
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2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately 
if I suffer unusual symptoms.  
8.  I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital.  
9. I am also aware that the investigator may terminate my participation in the study 
at any time, for any reason, without my consent.  
10. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
11. I have understood that my identity will be kept confidential if my data are 
publicly presented. 
12. I have had my questions answered to my satisfaction. 
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13. I have decided to be in the research study. 
14. I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form, I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given 
a copy of this consent document. 
For adult participants: 
Name and signature of the participant  
Name  :________________________  
Signature  : _______________________  
Date  : ________________ 
Name and Signature of the investigator or his representative obtaining 
consent: 
Name  :________________________  
Signature  : _______________________  
Date  : ________________ 
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INFORMATION TO PARTICIPANTS 
Investigator  : Dr S EDMIN JENITTA 
Name of Participant :  
Study title : To Study the Effects of Gastro-hepatic pack in the 
Type II Diabetes Mellitus  
You are invited to take part in this research study. The information in this 
document is meant to help you decide whether or not to take part. Please feel free 
to ask if you have any queries or concerns. You are being asked to participate in 
this study being conducted in Government Yoga & Naturopathy Medical College 
& Hospital, Chennai – 600 106 
The purpose of the research study is to Study the Effects of Gastro-hepatic 
pack in Type II Diabetes Mellitus  
Study Procedure:  
30 patient among you will be given gastro-hepatic pack for a duration of 30 
minutes. 30 patient among you will be given naturopathic and yogic 
interventions.The treatment is given 5 days in a week for 4 weeks. The hot water 
bag (98 to 104 degree F) is kept on the abdominal region, covering the epigastric 
region, left and right hypogastric region, left and right lumbar region and umbilical 
region. The ice bag (55 to 65 degree F) covers the region of lumbar vertebrae L2, 
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L3, L4 and L5. The treatment is administered in supine lying position, where the 
hot fomentation bag is kept over the abdominal region and then the ice bag on lower 
back region. The patients are then covered with cotton cloth and wrapped with 
woollen blanket.  
Possible Risks to you : Nil 
Possible benefits to you : Nil 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, sponsors, IEC and any person or agency 
required by law to view your data, if required. 
The information from this study, if published in scientific journals or presented 
at scientific meetings, will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decisions to not to participate in this research study will not affect your 
studies or your relationship with investigator or the institution.  
Can you decide to stop participating in the study once you start? 
89 
 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during course of the study without giving any 
reasons. 
However, it is advisable that you talk to the research team prior to stopping the 
participation. 
The results of the study may be intimated to you at the end of the study period. 
 
 
 
 
 
 
 
 
Signature of investigator                                                   Signature of participant 
Date: 
 
